Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need

Phase II Trial In Rare Kidney Disease Is A Success

 
• By Ayisha Sharma
Iptacopan Is Novartis' Lead Nephrology Asset • Source: Alamy

More from Genitourinary

More from Therapeutic Category